Premium
Evaluation of Intracavitary Chemotherapy Delivery for the Treatment of Mammary Carcinoma
Author(s) -
De Lille A.,
Rizzo S. A.,
Hudacheck S. F.,
Chubb L. S.,
Kwong G.,
Dernell W. S.
Publication year - 2005
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5810.2005.0064r.x
Subject(s) - paclitaxel , medicine , tolerability , chemotherapy , poloxamer , poloxamer 407 , metastasis , in vivo , drug delivery , urology , pharmacology , pathology , surgery , cancer , adverse effect , chemistry , biology , microbiology and biotechnology , organic chemistry , copolymer , polymer
The purpose of this study was to evaluate tolerability and efficacy of local (intracavitary) delivery of paclitaxel from a gel polymer (poloxamer 407) following marginal (histologically incomplete) resection of mammary carcinoma in a mouse model Methods: In vitro sensitivity to paclitaxel as well as poloxamer‐taxol mixture (polotax) was determined for 4 human breast tumor cell lines using the MTS‐assay (Promega). Nude mice were then injected with MCF‐7/ADR (Adriamycin R resistant) cells. Tumor growth was monitored by imaging of luciferase activity with a CCD camera (IVIS system, Xenogen). Primary tumors were allowed to grow to 3 different size ranges. At the time of primary tumor resection, animals were randomly assigned to treatment groups comparing intracavitary (in the wound) polotax to intravenous paclitaxel. Mice were imaged weekly to evaluate tumor regrowth and metastasis. Results: All cells lines demonstrated sensitivity to paclitaxel and three of the four cell lines demonstrated improved cytotoxicity with polotax compared to drug delivered alone. One of 9 mice treated with polotax had local regrowth (by 60 days) compared to 6 of 9 mice treated with intravenous paclitaxel. One of 9 mice treated with polotax had distant metastasis at 60 days compared to 5 of 8 mice treated with intravenous paclitaxel. These effects were seen with tumors of all sizes. Discussion/Conclusions: Poloxamer delivery of paclitaxel appears to result in improved efficacy compared to paclitaxel alone. Improved local and systemic control of mammary carcinoma is seen following intracavitary poloxamer delivery of paclitaxel compared to paclitaxel alone in this mouse model.